Morgan Stanley Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $730.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price cut by Morgan Stanley from $788.00 to $730.00 in a research report released on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $900.00 to $700.00 in a research report on Monday, May 18th. Canaccord Genuity Group decreased their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Finally, Cantor Fitzgerald decreased their price target on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $787.67.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $664.52 on Wednesday. The company’s 50 day moving average is $645.30 and its two-hundred day moving average is $722.39. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market cap of $70.25 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.47 and a beta of 0.24. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the business posted $8.22 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 37.33 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Insigneo Advisory Services LLC raised its holdings in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Arjuna Capital lifted its holdings in shares of Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC boosted its position in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 14 shares in the last quarter. TD Private Client Wealth LLC increased its position in Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 15 shares in the last quarter. Finally, MCF Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 15 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.